Abstract
Mechanical valve thrombosis is a feared complication in pregnant women with mechanical heart valves (MHV). It is associated with a high maternal and foetal morbidity and mortality. Optimal anticoagulation strategies for pregnant women with MHV remain controversial. Vitamin K antagonists (VKA) are the most effective treatment regimen to prevent valve thrombosis and are therefore considered the safest treatment for the mother. However, VKAs increase the risk of embryopathy, foetopathy, foetal haemorrhage and foetal loss. A particular challenge is to balance the need for adequate anticoagulation for MHV during pregnancy against the risk of bleeding, teratogenicity and fetotoxicity. In this case series, we describe complexity of the management of anticoagulation in pregnant patients with MHV, and describe 2 treatment approaches in patients with MHV thrombosis. Our case series high-lights that anticoagulation strategy should be individualised, and that best management is provided by a multidisciplinary cardio-obstetric team.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
